Skip to main content

Table 2 Number of patients, antihypertensive prescriptions and baseline ACEIs prescription proportion in the 13 UK regions

From: The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Regions Baseline ACEIs prescription proportion (%) ACEIs prescription proportion (%) at the end of the study Total number of prescriptions Total number of patients
High baseline ACEIs prescription proportion (>74 %)
  North East 80.8 74.2 1,143,760 13,319
  South East 74.7 71.6 3,865,373 53,299
  Wales 74.4 74.1 6,185,924 63,467
  East Midlands 74.3 75.8 1,364,324 22,370
Intermediate baselineACEIs prescription proportion (65 %-74 %)
  Yorkshire and the Humber 73.5 73.6 1,554,143 20,968
  East of England 72.5 72.1 3,505,910 52,733
  South Central 71.7 70.9 5,030,800 69,175
  Scotland 72.2 70.8 3,760,187 62,610
  West Midlands 69.5 68.5 3,764,019 52,920
  North West 69.2 70.8 6,279,440 80,575
  London 69.1 70.9 3,401,591 57,108
Low baseline ACEIs prescription proportion (<65 %)
  South East Coast 63.6 63.8 3,698,109 52,221
  Northern Ireland 60.3 65.5 801,164 15,256
  1. ACEIs Angiotensin converting enzyme inhibitors